Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 20 November 2023, 16:05 HKT/SGT
Share:
    

Source: Eisai
LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

TOKYO and CAMBRIDGE, Mass., Nov 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline.

The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.

The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates LEQEMBI as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline, which acts on the underlying pathology of AD.

The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare. It was awarded for the success of the Phase III Clarity AD study of LEQEMBI.

Eisai and Biogen deeply appreciate the cooperation of people living with AD and healthcare professionals who participated in LEQEMBI’s clinical studies.

AD is a progressive, fatal disease, and a global healthcare issue that greatly impacts not only the people living with the disease, but also their loved ones, care partners and society. Eisai and Biogen will deliver LEQEMBI to the people with early AD who need it, as well as aim to continue creating impact on global issues surrounding dementia.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product. Eisai has the final decision-making authority.

Please see full Prescribing Information, including Boxed WARNING in the United States.

For more information, visit www.eisai.com/news/2023/news202370.html

Media Contacts:

Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Biogen Inc.
Jack Cox + 1-781-464-3260
public.affairs@biogen.com




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 12, 2024 11:56 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 11, 2024 09:00 HKT/SGT
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong
July 2, 2024 12:01 HKT/SGT
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
June 28, 2024 14:57 HKT/SGT
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
June 21, 2024 14:35 HKT/SGT
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
June 10, 2024 17:50 HKT/SGT
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
June 3, 2024 16:08 HKT/SGT
Eisai Named to List of The Time 100 Most Influential Companies
June 3, 2024 14:22 HKT/SGT
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
May 28, 2024 14:19 HKT/SGT
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 23, 2024 17:07 HKT/SGT
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: